Lipitor Holds Key to DTC Ad Spending in 2012

As reported by Nielsen, direct-to-consumer (DTC) advertising spending by the pharmaceutical industry was down by 1% compared to 2010. I did a little exercise to predict that DTC spending in 2012 will see a further 3% decrease compared to 2011 solely due to an expected drop in Lipitor advertising. Here's how I came up with that estimate.

Pharma Marketing News Vol. 11, No. 10: 15 November 2012

Welcome to Volume 11, Issue #10 (15 November 2012) of Pharma Marketing News.

Sanofi US Diabetes Team Wins 3rd Annual Pharmaguy Social Media Pioneer Award

PharmaGuy (aka John Mack) presented the coveted bright yellow Hawaiian shirt/Pharmaguy Social Media Pioneer Award to Dennis Urbaniak, VP, Joan Mikardos, Senior Director, and Laura Kolodjeski, Senior Manager, Patient Solutions, at Sanofi US Diabetes. The award was made at the 6th Annual Digital Pharma East conference in Philadelphia on October 17, 2012. Accepting the award on behalf of the winners -- who could not make it in person -- was Wendy Blackburn of Intouch Solutions.

Pharma Responds to FDA’s Draft DTC Guidelines

FDA has received several comments from the pharmaceutical industry regarding the agency's 'Draft Guidance for Industry Direct-to-Consumer Television Advertisements.' This article reviews the comments submitted by PhRMA, Sanofi, and Shire. Comments from other pharma companies addressed similar issues to the ones reviewed here.

The Year 2012 in Images: A Select Review of Pharma Industry News & Trends

These are Pharmaguy's favorite images and stories published on Pharma Marketing Blog during 2012. It's a good summary of some of the major trends in the industry.

Do Drug Copay Coupons Drive Up Healthcare Costs?

Coupons for drug co-payments are illegal and drive up long-term health-care costs for all, a consumer group and four trade-union health-insurance plans said in announcing lawsuits against eight pharmaceutical companies. The lawsuits claim that although coupons reduce the consumer's out-of-pocket cost, the health insurer still pays the previously negotiated price to the drug company. With no savings from generics, health plans will need to charge patients more to keep up with rising costs, the lawsuits say.

The Role of Social Media in Managaing Chronic Diseases

The Role of Social Media in Managaing Chronic Diseases Focus on Diabetes and ObesityIn an "Open letter to NPR about Diabetes Social Media piece,"...

Is Your Marketing Head in the Cloud? The Appature Nexus Marketing Cloud Software Platform

Appature, a unique software-as-a-service provider, sees this as an immense opportunity to couple the vast amount of data available to healthcare marketers with relationship marketing technology to discover new methods to personalize and optimize campaigns to both consumers and healthcare professionals. This article reviews Appature Nexus, a Marketing Cloud software platform that drives sales growth through an integrated marketing database, campaign management tool and reporting/analytics engine.

Mobile Regulatory Fears: PhRMA Raises an Alarm

In a blog post provocatively titled 'An App for That, But For How Much Longer?', PhRMA's Kate Connors agreed with a Washington Times op-ed piece that suggested the FDA will soon require apps such as medication prescription renewal reminders and blood glucose level tracking functions to be regulated as medical devices. The op-ed author, Joel White, executive director of the Health IT Now Coalition, suggests that this effort would lead to increased costs as well as constraints on user access to these apps, which 'may cause developers to move on to other, less burdensome endeavors.' 'In the end, this could hinder the way that patients can actively improve their own care,' said Conners. Is this fear warranted? Are there apps that SHOULD be regulated by the FDA? Read this article and find out.

Some Unregulated Physician Smartphone Apps May Be Buggy

Practically every pharmaceutical company has one or more apps. The ones I am interested in are apps designed to help doctors in their diagnosis of patients. Big among these are the
- Advertisement -